1. Home
  2. STXS vs CCCC Comparison

STXS vs CCCC Comparison

Compare STXS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

HOLD

Current Price

$2.68

Market Cap

210.0M

Sector

Health Care

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.15

Market Cap

208.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STXS
CCCC
Founded
1990
2015
Country
United States
United States
Employees
N/A
110
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.0M
208.4M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
STXS
CCCC
Price
$2.68
$2.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$4.00
$7.25
AVG Volume (30 Days)
571.4K
1.6M
Earning Date
03-02-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$30,075,000.00
$30,108,000.00
Revenue This Year
$24.21
N/A
Revenue Next Year
$29.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.62
N/A
52 Week Low
$1.54
$1.09
52 Week High
$3.59
$3.84

Technical Indicators

Market Signals
Indicator
STXS
CCCC
Relative Strength Index (RSI) 56.60 47.25
Support Level $2.59 $2.06
Resistance Level $2.82 $2.23
Average True Range (ATR) 0.14 0.15
MACD 0.02 0.02
Stochastic Oscillator 63.21 32.99

Price Performance

Historical Comparison
STXS
CCCC

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: